China Sky One Starts Shift From OTC To Prescription Market
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China Sky One Medical entered 11 new drugs enter into clinical trials, seven of which are injectable drugs, the company announced June 10, which could lead to the company's first foray into the injectable drug market in China
You may also be interested in...
A Very Good Time For Acquisitions – China Sky One Sees Opportunities In Financial Crisis
SHANGHAI - China Sky One Medical will take the opportunity presented by the world financial crisis to look for companies to acquire with weak capital bases, the company's CEO says
A Very Good Time For Acquisitions – China Sky One Sees Opportunities In Financial Crisis
SHANGHAI - China Sky One Medical will take the opportunity presented by the world financial crisis to look for companies to acquire with weak capital bases, the company's CEO says
China Sky One Moves to NASDAQ To Raise Brand Awareness
SHANGHAI - Hoping to increase visibility with foreign investors, China Sky One Medical received approval to list its common stock on the NASDAQ Global Market, the company announced Sept. 2